Cloudbreak Pharma (2592 HK)

Cloudbreak Pharma is a clinical-stage ophthalmology biotechnology company dedicated to developing novel and differentiated treatments for eye diseases, leveraging its proprietary Multi-Kinase Inhibitor (MKI) platform. Its pipeline includes lead candidates such as CBT-001 for pterygium and CBT-004 for pinguecula, both in late-stage clinical trials. The company was founded in 2015 and is headquartered in Irvine, California, USA, with operations also in Mainland China and Hong Kong.